Tissue proteomics · progression biology · orthogonal validation

From proteome-wide change to a progression-linked pathway.

An anonymous demonstration of how label-free tissue proteomics can compare histological grades, identify a coordinated biological pathway, prioritize candidate proteins, and test the strongest signals with an independent tissue-based method.

Explore candidates Review the workflow

Tissue gradesprogression-aware comparison

Label-freebroad quantitative proteomics

Pathway viewcoordinated biological signal

Orthogonalindependent tissue validation

Anonymousmodified demonstration values

Analytical workflow

Progression requires more than a two-group comparison.

The analysis must preserve ordered tissue grades, separate broad screening from biological interpretation, and verify whether candidate abundance and tissue localization follow the proposed progression pattern.

01 / DESIGN

Preserve grade structure

Reference tissue and progressively altered states remain distinct rather than being collapsed into one disease group.

02 / DISCOVER

Quantify broadly

Label-free LC–MS/MS screens the proteome for grade-associated abundance patterns.

03 / CONNECT

Review pathway coherence

Related proteins are evaluated together to distinguish a coordinated process from isolated hits.

04 / PRIORITIZE

Select candidates

Trend consistency, effect size, biological position, and validation suitability guide the shortlist.

05 / VALIDATE

Test in tissue

An orthogonal method examines abundance, localization, and association with histological progression.

Interactive candidate explorer

Which signals truly track progression?

Select an anonymous candidate to compare its modified grade profile, pathway role, discovery evidence, and orthogonal validation status.

Candidate 1

Cellular transport-associated signal

Priority progression candidate

Grade patternMonotonic increaseAbundance rose across progressively altered tissue states.

Pathway evidenceCoherentThe signal aligned with several proteins from the same cellular process.

Tissue validationSupportedIndependent staining retained the progression-associated direction.

Interpretation: Candidate 1 combined an ordered discovery trend, pathway coherence, and orthogonal tissue support. It remains a research candidate rather than a clinically validated biomarker.

Progression profile

Modified representative values show the selected candidate across reference tissue and three ordered histological states.

Illustrative values only. Scale, uncertainty, and group structure do not reproduce the publication.

Orthogonal validation lens

The validation stage asks whether a discovery signal is visible by an independent tissue method and whether its localization supports the biological interpretation.

Independent tissue signalDetected

Direction across gradesConsistent

Localization relevanceBiologically plausible

Clinical validationStill required

Important: orthogonal tissue evidence can strengthen a mechanistic or progression claim. It does not establish diagnostic accuracy, prospective performance, or clinical utility.

What this demonstrates

Progression evidence is a pattern, not a single p-value.

The strongest candidates connect ordered abundance change, pathway-level coherence, tissue localization, and independent validation while keeping the final claim within the available evidence.

Model ordered biological states

Do not erase progression information by reducing all altered tissue to one category.

Interpret proteins in context

Use pathway coherence to judge whether several signals support the same biological process.

Challenge the discovery result

Use an independent measurement principle to evaluate abundance and localization.

Separate progression from diagnosis

A progression-linked candidate is not automatically a diagnostic or prognostic biomarker.

Demonstration scope

Scientific logic retained. Study identity removed.

This public-facing case is derived from a peer-reviewed quantitative tissue-proteomics workflow. It is not a reproduction of the publication or a clinical validation report.

What remains scientifically representative

Comparison of reference tissue with ordered histological grades.
Label-free quantitative proteomics for broad discovery.
Pathway-guided prioritization of progression-associated candidates.
Orthogonal tissue validation of selected protein signals.

What has been anonymized or modified

Disease identity, authors, institutions, cohort sizes, protein identities, exact pathway terminology, thresholds, instruments, dates, and empirical values are omitted or changed.

What the example does not claim

Candidate labels do not map publicly to original proteins.
Displayed values are illustrative and are not clinical performance metrics.
No patient, client, employer, or unpublished information is disclosed.

All identifying and exact empirical details have been removed or modified for this website demonstration.